Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Effect of n-3 Polyunsaturated Fatty Acids in Patients With Psoriatic Arthritis

This study has been completed.
Information provided by (Responsible Party):
Salome Kristensen, Aalborg Universitetshospital Identifier:
First received: March 20, 2013
Last updated: February 17, 2016
Last verified: February 2016

Background: There is evidence for a high cardiovascular risk in rheumatic and inflammatory diseases . Recent evidence suggest that psoriatic arthritis is also associated with an increased cardiovascular risk with accelerated atherosclerosis and increased cardiovascular risk. However, data regarding cardiovascular comorbidity and cardiovascular risk factors in patients with psoriatic arthritis are limited.

Objective: The aim of this study is to investigate the effect of daily supplementation with 3 g n-3 polyunsaturated fatty acids on risk markers for cardiovascular disease and inflammation in patients with psoriatic arthritis.

Design: Randomized double-blind, placebo-controlled, multicenter trial with n-3 polyunsaturated fatty acids in patient with psoriatic arthritis.

Setting: Departments of Rheumatology, Nephrology and Cardiology at Aalborg University Hospital and Vendsyssel Hospital in Region Northern Denmark

Participants: 156 men and women aged > 18 years with psoriatic arthritis classified by the CASPAR criteria will be included. Exclusion criteria: cardiac arrhythmias, conduction disturbances, treatment with biological drugs or oral corticosteroids. Inclusion time: spring 2013 to spring 2015.

Method: The following data will be collected for each participant: Interview including dietary records, assessment of tender and swollen joints, enthesitis, dactylitis, patient global assessment of disease activity (Visual Analogue Scale ), global assessment of pain (Visual Analogue Scale), psoriatic skin involvement by Psoriatic Area and Severity Index (PASI), laboratory parameters of disease activity and risk markers of cardiovascular disease.

For detection of early cardiovascular risk markers Heart Rate Variability (HRV) and Pulse Wave Velocity (PWV) will be performed.

Main outcome measures: The primary endpoint will be HRV and secondary endpoints will be PWV, inflammatory activity and use of analgesics.

The trial is approved by The local Ethics Committee, registration number N20120076

Condition Intervention
Psoriatic Arthritis
Dietary Supplement: n-3PUFA
Dietary Supplement: olive oil

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: The Effect of n-3 Polyunsaturated Fatty Acids on Risk Markers for Cardiovascular Disease and Inflammation in Patients With Psoriatic Arthritis

Resource links provided by NLM:

Further study details as provided by Aalborg Universitetshospital:

Primary Outcome Measures:
  • Change in HRV measure [ Time Frame: Baseline and 24 week ]
    Heart Rate Velocity, non-invasive measurement for the autonom regulation of the heart associated with risk of cardiovascular disease

Secondary Outcome Measures:
  • Change in PWV [ Time Frame: Baseline and 24 weeks ]
    Pulse wave Velocity, non-invasive measurement for arterioscleroses

Other Outcome Measures:
  • Change in Inflammation parameters [ Time Frame: Baseline and 24 weeks ]
    Disease activity score for psoriatic arthritis, Psoriasis area severity index, enthesitis score, CRP

Enrollment: 145
Study Start Date: March 2013
Study Completion Date: December 2015
Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: n-3PUFA
n-3 polyunsaturated fattyacids from fish oil
Dietary Supplement: n-3PUFA
Other Name: n-3 polyunsaturated fattyacids from fishoil
Placebo Comparator: olive oil
Olive oil
Dietary Supplement: olive oil

  Show Detailed Description


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and women aged > 18 years with
  • Psoriatic arthritis classified by the CASPAR criteria
  • written informed consent

Exclusion Criteria:

  • Treatment with biological drugs
  • Treatment with oral corticosteroids
  • cardiac arrhythmias
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01818804

Aalborg University Hospital, Department of Rheumatology
Aalborg, Denmark, 9000
Vendsyssel Hospital in Region Northern Denmark, Department of Rheumatology
Hjørring, Denmark, 9800
Sponsors and Collaborators
Aalborg Universitetshospital
Principal Investigator: Salome Kristensen, MD Aalborg Universityhospital, Department og Rheumatology
Study Director: Jeppe H Christensen, Professor Aalborg University Hospital, Department of Nephrology
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Salome Kristensen, MD, Aalborg Universitetshospital Identifier: NCT01818804     History of Changes
Other Study ID Numbers: N-20120076
Study First Received: March 20, 2013
Last Updated: February 17, 2016
Individual Participant Data  
Plan to Share IPD: Yes

Additional relevant MeSH terms:
Arthritis, Psoriatic
Joint Diseases
Musculoskeletal Diseases
Spinal Diseases
Bone Diseases
Skin Diseases, Papulosquamous
Skin Diseases processed this record on April 28, 2017